Answers are grounded in this paper and cite their sources.
Retrospective study shows seroconversion affects endoscopic remission in Crohn's disease, suggesting potential treatment implications.
ANA non-seroconversion at 6 months was associated with higher rates of endoscopic remission and a lower likelihood of developing antibodies against infliximab.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: